MLR Maelor

RNS Number:5093G
Maelor PLC
29 October 2007



Maelor plc


29 October 2007



                                   Maelor plc



MAELOR and HELSINN ANNOUNCE A LICENSE AGREEMENT FOR ALOXI(R) (PALONOSETRON) IN
THE UK



LONDON, UNITED KINGDOM AND LUGANO, SWITZERLAND, OCTOBER 29th, 2007  - MAELOR PLC
(AIM:MLR), a UK based specialist hospital medicines group and HELSINN HEALTHCARE
SA , a Swiss pharmaceutical group, announce the signing of an agreement granting
MAELOR the exclusive License and Distribution rights for Aloxi(R) (palonosetron
hydrochloride) in the UK.

Aloxi(R) is a patented new generation 5-HT3 antagonist, which is differentiated
by its strength on initiation and the duration of its activity.

Aloxi(R) obtained a centralised registration in Europe in 2005, with an
indication for the prevention of acute nausea and vomiting associated with
highly emetogenic cancer chemotherapy, and the prevention of nausea and vomiting
associated with moderately emetogenic cancer chemotherapy.



Aloxi(R) is successfully marketed in 40 countries, with annual sales in 2006 of
$323M worldwide, according to IMS figures.



Under the terms of the agreement MAELOR have also acquired the rights to an oral
formulation and an extended indication for the management of post operative
nausea and vomiting, which are in development.

 "We are delighted to sign this new agreement with MAELOR and look forward to
initiating a successful co-operation for Aloxi(R) in the UK", said Dr. Riccardo
Braglia, CEO of HELSINN HEALTHCARE SA. "MAELOR have demonstrated their ability
to grow products in the specialist hospital medicines market, while the patients
and the medical community in the UK will enjoy the benefits of an innovative
antiemetic like Aloxi(R)"



"HELSINN HEALTHCARE have done a first class job of developing Aloxi(R) and we
are delighted to become their UK partner for this product", said Mr. Tim Wright,
CEO of MAELOR. "We have made clear our strategy of building the MAELOR group
through the acquisition and organic growth of specialist hospital medicines. The
licensing of Aloxi(R) is another example of our commitment and delivery against
this strategy. Aloxi(R) is an excellent fit in our growing portfolio and we look
forward to driving its growth both with the current and future indications or
formulations."





                                   -   Ends -





About Chemotherapy-Induced Nausea and Vomiting (CINV)

CINV is estimated to potentially affect 85% of cancer patients undergoing
chemotherapy and can result in a delay or discontinuation of chemotherapy
treatments. The supportive care area is becoming of paramount importance to help
patients deal with adverse events of anti-cancer therapies. With good supportive
care drugs, cancer patients are able to tolerate the anti-cancer treatment to a
greater extent, improving the chances of completing their treatment course
successfully and with a better quality of life.

About Aloxi(R)

Aloxi(R) is a selective 5-HT3-receptor antagonist, developed for the prevention
of CINV, with a long half-life of 40 hours and at least 30 times higher receptor
binding affinity than currently available compounds. Since its availability in
USA in September 2003, there have been over 6.9 million successful uses of Aloxi
(R). The product has shown to be effective in preventing both acute and delayed
CINV in patients receiving emetogenic chemotherapies. For more information about
this product please visit our website: www.aloxi.com.



About HELSINN HEALTHCARE

HELSINN HEALTHCARE SA is a privately owned pharmaceutical group with
headquarters in Switzerland and is the worldwide licensor of Aloxi(R). HELSINN's
core business is the licensing of pharmaceuticals in niche therapeutic areas.
The company's business strategy is to in-license early-stage new chemical
entities and complete their development from the performance of pre-clinical/
clinical studies and CMC development to the attainment of market approvals in
strategic markets (U.S. and Europe). HELSINN's products are eventually
out-licensed to its marketing partners for distribution. The active
pharmaceutical ingredients and the finished dosage forms are manufactured at
HELSINN's cGMP facilities and supplied worldwide to its customers. For more
information about HELSINN, please visit www.helsinn.com.

Contact person HELSINN:

Rachid BenHamza, Ph.D. - Head Business Unit Oncology & Supportive Care
Tel: +41 91-985-21-21. info-hhc@helsinn.com


About MAELOR

Maelor plc (AIM:MLR) is a fast growing specialist hospital medicines group,
which is traded on the Alternative Investment Market ("AIM").  The strategy of
the Group is to grow by combining the acquisition of products and companies with
the dynamic development and marketing of these assets. With a focus in the
specialist hospital sector, Maelor leverages its expertise in both
pharmaceuticals and medical devices to drive growth.

Based in the UK, Maelor commercialises its portfolio in the UK directly.  Maelor
also operates internationally through a strong network of distributors.
Currently focused in the areas of critical care, neurology and oncology, some of
Maelor's leading brands include:

Critical Care:  Volpex(R) (plasma substitute), Cryogesic(R) / DermogesicTM
(cryo-analgesic), Haemopressin(R) (oesophageal varices), ISOplex(R) (isotonic
plasma substitute)


Neurology: Mysoline(R) (primidone), a product currently used to treat Epilepsy
and which Maelor are developing for management of Essential Tremor, a
distressing condition affecting an estimated 1 in 25 over 40 year olds for which
primidone is one of only two recommended treatments.

Oncology: Cryogesic(R), 5 FU (oral chemotherapeutic) and most recently, Aloxi(R)
(chemotherapy induced nausea and vomiting)

Products which are outside of the Group's core hospital focus or are in early
stage of research are out-licensed, including the successful OptiFloTM  Catheter
Maintenance Solutions, a trademark of C.R. Bard Inc or an affiliate (to Bard
Limited) and Micelle Lidocaine, an early stage product for interstitial cystitis
(to Plethora Solutions Limited). To find out more about Maelor go to
www.maelor.plc.uk.


Enquiries MAELOR:

Maelor plc
Tel: +44(0) 1244 625150
Tim Wright - CEO   www.maelor.plc.uk


Financial Dynamics Limited                             Tel: +44(0) 20 7831 3113
Billy Clegg / Edward Westropp

Noble & Company Limited                                Tel: +44(0) 20 7763 2200
Matthew Hall / Sam Reynolds







                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCUKOWRBBRRURA

Maelor (LSE:MLR)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024

Maelor (LSE:MLR)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024